Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration
In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments.
You may also be interested in...
Bluebird Revises Business Priorities And Secures Upfront Cash From Bristol
The company is deferring investment in a US commercial team and prioritizing R&D activities, but it outlined an accelerated path to approval for LentiGlobin in sickle cell disease.
NIH Partnership To Pick COVID-19 Therapeutics For Clinical Trials; Results Anticipated By Summer
NIH public-private partnership with FDA, CDC, BARDA and 16 biopharma companies to rank most promising therapeutics and vaccines to advance into clinical trials; candidates expected to be tested simultaneously under master protocol.
As Calls For Patent Sharing To Fight Pandemic Intensify, Manufacturing May Be Bigger Issue
Scientists and lawyers ask companies to temporarily license their IP for free, as others advocate compulsory licenses; real issue may be the ability to make a COVID-19 treatment or vaccine widely available.